公开(公告)号：US20230416357A1

公开(公告)日：2023-12-28

申请号：US18253240

申请日：2021-12-06

申请人： UCB BIOPHARMA SRL

发明人： Joseph Michael David RASTRICK ,  John Paul SILVA ,  Kerry Louise TYSON ,  Peter Charles ELLIOTT ,  Seppe Frans Roman LEYSEN ,  Zainab AHDASH

IPC分类号： C07K16/24

CPC分类号： C07K16/244 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/34 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/33

摘要： The present invention relates to antibodies binding to IL22 and inhibiting its interaction with one or more of its natural ligands Specific examples of such antibodies are provided. The therapeutic uses of the antibodies and methods of generating such C are also provided.

公开(公告)号：US11786593B2

公开(公告)日：2023-10-17

申请号：US17078127

申请日：2020-10-23

申请人： UCB BIOPHARMA SRL

发明人： Sam Philip Heywood ,  Gavin Barry Wild ,  Razwan Hanif ,  Christopher John Le Page

IPC分类号： A61K39/395 ,  C07K1/113 ,  C07K16/28 ,  C07K16/18 ,  C07K5/12 ,  C07C323/12 ,  C07C323/25

CPC分类号： A61K39/39591 ,  C07K1/1133 ,  C07K1/1136 ,  C07K16/18 ,  C07K16/2878 ,  C07C323/12 ,  C07C323/25 ,  C07K5/123 ,  C07K2317/31

摘要： The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.

公开(公告)号：US20230295657A1

公开(公告)日：2023-09-21

申请号：US18021005

申请日：2021-08-11

申请人： UCB BIOPHARMA SRL

发明人： NIKITA DALAL ,  AMI KABADI ,  TOSHAL ROHIT PATEL ,  PATRICK MARK DOWNEY ,  AMULYA NIDHI SHRIVASTAVA

IPC分类号： C12N15/86 ,  C07K14/47 ,  A61K48/00

CPC分类号： C12N15/86 ,  C07K14/4702 ,  A61K48/0066 ,  C12N2750/14143 ,  C12N2830/008

摘要： The present invention relates to nucleic acid constructs comprising methyl CpG binding protein 2 (MeCP2) promoter sequences. The present invention further relates to vectors, viral vector host cells and pharmaceutical compositions comprising said nucleic acid constructs. The present invention also concerns the therapeutic use of said nucleic acid constructs, vectors, viral vectors and pharmaceutical compositions.

公开(公告)号：US20230287100A1

公开(公告)日：2023-09-14

申请号：US18045623

申请日：2022-10-11

申请人： UCB BIOPHARMA SRL

发明人： Sophie Glatt ,  Lucian Ionescu ,  Margaret Jones ,  Ruth Oliver ,  Stevan Graham Shaw ,  Foteini Strimenopoulou ,  Venkata Pavan Kumar Vajjah

IPC分类号： C07K16/24 ,  A61P17/06 ,  A61P19/02

CPC分类号： C07K16/244 ,  A61P17/06 ,  A61P19/02 ,  A61K2039/505

摘要： The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.

公开(公告)号：US20230271951A1

公开(公告)日：2023-08-31

申请号：US17995495

申请日：2021-04-06

申请人： UCB BIOPHARMA SRL

发明人： Prafulkumar Tulshibhai CHOVATIA ,  Anne Marie FOLEY ,  Gregory William HASLETT ,  Martin Clive HUTCHINGS ,  James Andrew JOHNSON ,  Fabien Claude LECOMTE ,  Nathaniel Julius Thomas MONCK ,  Joanna Rachel QUINCEY ,  Konstantinos RAMPALAKOS ,  James Thomas REUBERSON ,  Adam Peter SMALLEY ,  Giancarlo TRANI ,  Darshan Gunvant VAIDYA

IPC分类号： C07D413/14 ,  A61K45/06 ,  C07D403/14 ,  C07D413/12 ,  C07D471/04 ,  C07D235/24 ,  C07D403/12

CPC分类号： C07D413/14 ,  A61K45/06 ,  C07D235/24 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D471/04

摘要： A series of substituted 4,4-difluorocyclohexyl derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

公开(公告)号：US11674967B2

公开(公告)日：2023-06-13

申请号：US17013326

申请日：2020-09-04

申请人： UCB BIOPHARMA SRL

发明人： James Philip O'Connell ,  John Robert Porter ,  Alastair Lawson ,  Boris Kroeplien ,  Stephen Edward Rapecki ,  Timothy John Norman ,  Graham John Warrellow ,  Tracy Lynn Arakaki ,  Alex Buntin Burgin ,  William Ross Pitt ,  Mark Daniel Calmiano ,  David Andreas Schubert ,  Daniel John Lightwood ,  Rebecca Jayne Munro

IPC分类号： G01N33/68 ,  C07D401/14 ,  C07K14/525 ,  C07D471/00 ,  C07K14/705 ,  C07K16/24 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D471/04 ,  A61K47/64 ,  A61P37/00 ,  A61P35/00

CPC分类号： G01N33/6845 ,  A61K47/6425 ,  A61P35/00 ,  A61P37/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D401/14 ,  C07D471/00 ,  C07D471/04 ,  C07K14/525 ,  C07K14/70575 ,  C07K16/241 ,  G01N33/6854 ,  G01N33/6863 ,  C07K2317/55 ,  C07K2317/92 ,  G01N2333/525 ,  G01N2500/02

摘要： A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.

公开(公告)号：US20230176071A1

公开(公告)日：2023-06-08

申请号：US17923904

申请日：2021-05-06

申请人： UCB BIOPHARMA SRL

发明人： Anastasios SPILIOTOPOULOS ,  David James MCMILLAN ,  Michael John Wright ,  Sebastian KELM ,  Xiaofeng LIU ,  Daniel John LIGHTWOOD

IPC分类号： G01N33/68

CPC分类号： G01N33/6857

摘要： A method of identifying of amino-acid residues on a target protein that form a binding site of a molecule of interest. Such method relies on selection of relevant patches of solvent-accessible residues and testing of an array of mutated proteins for changes of binding properties. Such method is useful for determining binding sites (epitopes) of antibodies, ligands and related molecules.

公开(公告)号：US20230151108A1

公开(公告)日：2023-05-18

申请号：US17929026

申请日：2020-02-13

申请人： UCB BIOPHARMA SRL

发明人： David Alan COOK ,  Helen Margaret FINNEY ,  Stephen Edward RAPECKI

IPC分类号： C07K16/28 ,  C07K14/765 ,  A61P35/00

CPC分类号： C07K16/2896 ,  C07K16/2878 ,  C07K14/765 ,  A61P35/00 ,  A61K2039/505

摘要： The present invention relates to multispecific antibodies against a novel targets' combination of CD137 and CD9, and their use in the treatment of cancer and infectious diseases.

公开(公告)号：US20230125234A1

公开(公告)日：2023-04-27

申请号：US17929032

申请日：2020-02-13

申请人： UCB BIOPHARMA SRL

发明人： David Alan COOK ,  Helen Margaret FINNEY ,  Stephen Edward RAPECKI

IPC分类号： C07K16/28 ,  A61P35/00

摘要： The present disclosure relates to a bispecific anti CD44/anti CTLA4 antibody. The antibody construct has defined CDRs and variable chains sequences. The bispecific antibodies has improved activity on CDS and CD4 T cells compared to known antibodies.

公开(公告)号：US20230074381A1

公开(公告)日：2023-03-09

申请号：US17804934

申请日：2022-06-01

申请人： UCB Biopharma SRL

发明人： Helene Margaret Finney ,  Alastair David Griffiths Lawson ,  Stevan Graham Shaw ,  Bryan John Smith ,  Kerry Louise Tyson ,  Lara Kevorkian ,  Christoph Meier ,  Kaushik Sarkar ,  Paul Alan Atherfold

IPC分类号： C07K16/28 ,  G01N33/50 ,  G01N33/564 ,  G01N33/68 ,  A61K47/60 ,  A61K47/64 ,  A61K39/395

摘要： The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.